Drug updated on 11/15/2023
Dosage Form | Film-coated tablet (oral; 20 mg, 40 mg) |
Drug Class | Kinase inhibitors |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, previously treated with two or more tyrosine kinase inhibitors (TKIs).
- For the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase with the T315I mutation.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Scemblix (asciminib) Prescribing Information. | 2023 | Novartis Pharmaceuticals Corporation, East Hanover, NJ |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Assessment report: Scemblix. | 2022 | EMA |
Clinical and pharmacoeconomic combined report: asciminib (Scemblix). | 2022 | CADTH |